Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. - Test2 - elhamkhani - TriplyDB

Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist.

Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist.

http://www.wikidata.org/entity/Q33643067

about

Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date Neurobiology of chronic mild stress: parallels to major depression A brief history of the development of antidepressant drugs: from monoamines to glutamate Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.Innovative approaches to treatment - refractory depression: The ketamine story.Glutamatergic modulators: the future of treating mood disorders?Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics The role of ketamine in treatment-resistant depression: a systematic review.Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review.New targets for rapid antidepressant action.Rapid antidepressant changes with sleep deprivation in major depressive disorder are associated with changes in vascular endothelial growth factor (VEGF): a pilot study A biological pathway linking inflammation and depression: activation of indoleamine 2,3-dioxygenase.Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting.Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments.Ketamine and the next generation of antidepressants with a rapid onset of action Clinical predictors of ketamine response in treatment-resistant major depression.Ketamine as a promising prototype for a new generation of rapid-acting antidepressants.Novel glutamatergic agents for major depressive disorder and bipolar disorder.Dynamic regulation of NMDAR function in the adult brain by the stress hormone corticosterone Drug development in pediatric psychiatry: current status, future trends.A role of Yueju in fast-onset antidepressant action on major depressive disorder and serum BDNF expression: a randomly double-blind, fluoxetine-adjunct, placebo-controlled, pilot clinical study Antidepressant-like effects of low ketamine dose is associated with increased hippocampal AMPA/NMDA receptor density ratio in female Wistar-Kyoto rats Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression Ketamine for depression: where do we go from here?Baseline mood-state measures as predictors of antidepressant response to scopolamine.Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder Abnormal Anterior Cingulate N-Acetylaspartate and Executive Functioning in Treatment-Resistant Depression After rTMS Therapy BDNF - a key transducer of antidepressant effects.Acute administration of ketamine in rats increases hippocampal BDNF and mTOR levels during forced swimming test.Memantine for late-life depression and apathy after a disabling medical event: a 12-week, double-blind placebo-controlled pilot study.Human biomarkers of rapid antidepressant effects Ketamine as a novel antidepressant: from synapse to behavior.Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR The interactive effects of ketamine and magnesium upon depressive-like pathology.The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders.The role of adipokines in the rapid antidepressant effects of ketamine.Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.

P2860

Q21129276-46566085-2EF6-41D8-B624-3FDCD0D5BDF3 Q24602988-843E0C2D-5E86-473E-B424-A62AA39E45C0 Q27004490-EE765EC1-48AF-45FA-892D-BB445735BADA Q27026698-4DA6E123-88A9-4C86-A32D-4E849AD54DB5 Q27028050-3AB37ED6-EFE2-4A16-8F32-3178111DE565 Q30711088-D416AEE6-894E-4264-9DBA-164F442C7307 Q33874459-59CD2EBD-DA08-4840-9705-3D85BA9EA241 Q34082689-CBEB5935-D540-4E9A-A8CB-DA53DED4BCB9 Q34398007-23E5F518-4B24-4125-AA47-242AE478399A Q34444632-CAC27363-CA46-4022-B55C-2E533AC93A08 Q34449588-EFEBDC43-B789-44FA-AB61-4DE5AE5E1110 Q34475595-6DF664D8-186D-4AD9-B53C-A09AA91F3A2E Q34507177-AEEA0C4E-3CB6-47BE-9B95-34CB1C91EC17 Q34630614-240F838D-A93F-4587-857B-F6DB4D3A2BDC Q34631232-79B042B1-31DD-4929-B521-3EEFC1080125 Q34640986-DA6AE6F8-5437-45A1-9357-A866A75A956E Q34766451-7C049E5F-88C8-45D3-B231-35ED9747C02D Q34978041-B046FE5D-2E7A-454E-98F6-A66F21957FAD Q35026766-C3EC5F80-BADB-413F-BB58-AC014AD7FD10 Q35547495-031DD83E-5359-432C-A48E-F811BE580498 Q35661119-E5670E3F-91D4-4DD6-8D85-0DB8231E37F3 Q35804068-4DEAB1B5-AD84-447A-ACDB-7AE689F12050 Q35811894-E0C30661-3141-4EE1-9A8B-F6C9EF30E058 Q35939606-4FEF88D8-B086-44C7-820B-79B165478B2B Q36007530-87428F79-1675-4903-81E3-DC1CFBB4CCA8 Q36128314-295A1316-1DB1-4383-8ADF-42A936ED5647 Q36223372-63CA68D4-D313-4EA9-9885-FC968E9E8EDE Q36296905-C6531AD8-A978-4EDD-A863-B19CAB6CAFE4 Q36434538-EA0AFE34-110B-43F3-BCFE-0A173A1AC929 Q36588690-0C6C3200-773D-468D-9724-338AD754B348 Q36608239-45393992-3607-441E-B720-2E199401963A Q36610494-6325BDDE-6EE0-471B-9D23-F504B23FF091 Q36697606-4A030320-4FC2-499B-83DC-42CD35247EA1 Q36902074-5B8F2223-A54C-4B15-A2E3-D1A5A974949C Q36905864-0EB429F2-FDB5-4DCC-9AB2-7B235BCA3B98 Q37248524-5215CFD3-0DC0-429B-B85E-8A037B49CF17 Q37249086-58C8DA30-731C-428C-BB6D-105637374B77 Q37387700-6EC70785-91A1-49FA-AC84-1B7B4204EAB7 Q37418553-EDB0964C-DC04-4020-8BFB-23BFA9D9B15A Q37424333-6EFD963A-6402-4390-AB15-1FA36FC8318E

P2860

Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist.

http://www.wikidata.org/entity/Q33643067

description

2009 nî lūn-bûn

@nan

2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Brain-derived neurotrophic fac ...... methyl-D-aspartate antagonist.

@ast

Brain-derived neurotrophic fac ...... methyl-D-aspartate antagonist.

@en

type

label

Brain-derived neurotrophic fac ...... methyl-D-aspartate antagonist.

@ast

Brain-derived neurotrophic fac ...... methyl-D-aspartate antagonist.

@en

prefLabel

Brain-derived neurotrophic fac ...... methyl-D-aspartate antagonist.

@ast

Brain-derived neurotrophic fac ...... methyl-D-aspartate antagonist.

@en

P1433

Q33643067-4D4C87B5-70C8-46A1-BC2E-B386D04C3966

P1476

Q33643067-1C9FDFBA-56FB-447C-AAE2-0AEF296F7A2F

P2093

Q33643067-0EABD5CC-3C4D-4CA0-BE2D-C294FE4A88CC

Q33643067-267D23CE-E4D4-441E-BEC8-A2D25BB08912

Q33643067-6A52FB18-435C-4322-809F-25E40132D616

Q33643067-8FFE0785-5EF4-4667-9EA2-225A99D03656

Q33643067-C6700D11-C38B-4FFE-B409-7A6DA1D050D2

P2860

Q33643067-0B907EFF-3241-40E6-B376-49DC6278BA08

Q33643067-163D2EEA-9CDF-4507-9792-DAC21023BA90

Q33643067-1CC61E7A-0CC2-44B6-A4DB-286E39E6322B

Q33643067-2756EF55-9CA1-487E-9DED-A16FD334CD0F

Q33643067-2B08A946-09B0-4C50-89F8-4196DF6A4ABA

Q33643067-2BBDE6FF-830C-4030-8771-2FE7B40A7BDC

Q33643067-37E2BF48-CEEE-4C82-9F2A-2C5C95DF7CE2

Q33643067-3F6D411C-B09D-4F9A-88C4-D6C9E27824D2

Q33643067-3FE00162-C8E7-48D0-954A-3D419D3A7B83

Q33643067-437AC965-C841-422D-8AEA-5B6838E030A7

P304

Q33643067-EB178721-AF34-4D25-BB50-D7C4ACD298AB

P31

Q33643067-BEC1A5FD-F1A2-4B0F-B3F3-6F32F14027E4

P356

Q33643067-1858C9F1-65AA-4151-86DA-7DF17361BD38

P433

Q33643067-A36AFC12-0898-4A02-8906-4AEE4C4ECD58

P478

Q33643067-0174E4EA-11F8-43FD-9CB2-9D1B411112D4

P50

Q33643067-A32D1F78-E92A-4951-A6E9-E7CED37DD553

Q33643067-F1470152-4554-45F7-803B-FF572790DBA8

P577

Q33643067-59FE08F7-020D-4E2F-A373-5256A754962D

P5875

Q33643067-EC3DD6B4-1A19-4BCF-9F90-8314FDFADFF8

P698

Q33643067-4D8CB314-5BB9-484F-81D9-F9F05CF39AE2

P932

Q33643067-B95E772B-8453-4B26-8D61-36572A194ED3

P356

P1433

The Journal of Clinical Psychiatry

P1476

Brain-derived neurotrophic fac ...... -methyl-D-aspartate antagonist

@en

P2093

Carlos A Zarate

http://www.w3.org/2001/XMLSchema#string

David Luckenbaugh

http://www.w3.org/2001/XMLSchema#string

Husseini K Manji

http://www.w3.org/2001/XMLSchema#string

Nancy Brutsche

http://www.w3.org/2001/XMLSchema#string

Peixiong Yuan

http://www.w3.org/2001/XMLSchema#string

P2860

A rating scale for depression

Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications

Hippocampal brain-derived neurotrophic factor expression following treatment with reboxetine, citalopram, and physical exercise

A new depression scale designed to be sensitive to change

A neurotrophic model for stress-related mood disorders

Antidepressant effects of ketamine in depressed patients

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

A rating scale for mania: reliability, validity and sensitivity

Neurotrophins and depression.

Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants.

P304

1662-1666

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4088/JCP.08M04659

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P50

Rodrigo Machado-Vieira

Nancy Diazgranados

P577

2009-09-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26802695

http://www.w3.org/2001/XMLSchema#string

P698

19744406

http://www.w3.org/2001/XMLSchema#string

P932

2819547

http://www.w3.org/2001/XMLSchema#string